Part I of the study involves treating subjects who have HCV by giving them different doses and combinations of some or all of the following drugs: Debio 025, peginterferon alpha-2a and ribavirin for 4 weeks. Part II involves giving subjects peginterferon alpha-2a plus ribavirin for up to 68 weeks beyond the first month. At the end of Part I and Part II, the amount of HCV (viral load) in each subject will be analyzed (tested) to see if Debio 025 plus peginterferon alpha-2a and ribavirin is effective in treating long-term hepatitis C. The purpose of this study is: • To examine how Debio 025 plus peginterferon alpha-2a (180 ?g once weekly) and ribavirin (1000 or 1200 mg/day) affect the HCV viral load in subjects with long-term hepatitis C. • To investigate how safe Debio 025 is. • To determine how different dose levels of Debio 025 are tolerated. • To observe how quickly Debio 025 is removed from the body after dosing (called pharmacokinetics-PK). • To observe what the study drug does to the body after dosing (called pharmacodynamics PD) when Debio 025 has been given on its own and when it has been given in combination with peginterferon alpha-2a (180 ?g once weekly) and ribavirin (1000 or 1200 mg/day) to subjects with long-term hepatitis C.

Males and females between the ages of 18 and 60, serologically diagnose of chronic Hep C viral infection genotype 1 and weighs more than 50kg for females and more than 60kg for males with BMI between 18 and 32kb/m2

Part I of the study involves treating subjects who have HCV by giving them different doses and combinations of some or all of the following drugs: Debio 025, peginterferon alpha-2a and ribavirin for 4 weeks. Part II involves giving subjects peginterferon alpha-2a plus ribavirin for up to 68 weeks beyond the first month. At the end of Part I and Part II, the amount of HCV (viral load) in each subject will be analyzed (tested) to see if Debio 025 plus peginterferon alpha-2a and ribavirin is effective in treating long-term hepatitis C. The purpose of this study is: • To examine how Debio 025 plus peginterferon alpha-2a (180 ?g once weekly) and ribavirin (1000 or 1200 mg/day) affect the HCV viral load in subjects with long-term hepatitis C. • To investigate how safe Debio 025 is. • To determine how different dose levels of Debio 025 are tolerated. • To observe how quickly Debio 025 is removed from the body after dosing (called pharmacokinetics-PK). • To observe what the study drug does to the body after dosing (called pharmacodynamics PD) when Debio 025 has been given on its own and when it has been given in combination with peginterferon alpha-2a (180 ?g once weekly) and ribavirin (1000 or 1200 mg/day) to subjects with long-term hepatitis C.

(No information)